^
Association details:
| Biomarker: | ATM mutation + IGH mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Regimen: | (fludarabine IV + cyclophosphamide + Rituxan (rituximab)) |
| Direction: | Resistant |
Evidence:
Source:
Title:
GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE
Published date:
05/17/2018
Excerpt:
To analyze progression-free survival (PFS) according to the presence of genetic defects in CLL patients treated with front line FCR or BR regimen...we performed subsequent analyses separately according to the IGHV status; (c) clear negative impact of ATM mutations in patients with mut-IGHV (25 vs. 56 m in ATM-wt patients; P = 0.017).
